Abbott's Q3 earnings hit by costs
This article was originally published in Scrip
Executive Summary
Abbott Laboratories' net earnings dropped by 40% in the third quarter to $891 million, hit by costs associated with the acquisition of Solvay, higher rebates required under US healthcare reform, a baby formula product recall and sales returns associated with the withdrawal of the diet drug Meridia (sibutramine).
You may also be interested in...
UK Reimbursement Decisions Focus Mostly On Cancer
The UK's main reimbursement bodies made a series of decisions this week that were broadly favorable and largely focused on oncology medicines.
Deal Watch: Valeant Sells Off iNova To Finance Debt-Reduction Efforts
While troubled Valeant was divesting iNova to private equity investors, Novartis announced a pair of oncology-focused deals, out-licensing a brain cancer drug to Midatech and partnering with IBM Watson Health to optimize breast cancer treatment.
Pfizer/Astellas Amend Trial To Position Xtandi In Early Prostate Cancer
Astellas and Pfizer have amended the PROSPER trial protocol in a bid to position Xtandi ahead of Zytiga in the early stage prostate cancer market.
Need a specific report? 1000+ reports available
Buy Reports